EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSSFOG00015018135
Gene Symbol: PSMD6
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSSFOG00015014784
Gene Symbol: PSMD7
3 Cross references
219 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSSFOG00015005032
Gene Symbol: PSMD8
1 Cross references
210 Possible Orthologues:

Proteasome Subunit Alpha Type-1

Ensembl ID : ENSSFOG00015012567
Gene Symbol: LOC108934589
3 Cross references
268 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSSFOG00015010531
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSSFOG00015025267
Gene Symbol: LOC108922755
3 Cross references
105 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSSFOG00015028916
Gene Symbol: LOC108937954
3 Cross references
208 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSSFOG00015030620
Gene Symbol: LOC108922574
3 Cross references
218 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSSFOG00015018237
Gene Symbol: LOC108935608
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSSFOG00015014825
Gene Symbol: LOC108922574
3 Cross references
218 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSSFOG00015016116
Gene Symbol: LOC108930389
3 Cross references
209 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSSFOG00015010853
Gene Symbol: PRMT5
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).